[go: up one dir, main page]

US20180193637A1 - Process and system for iontophoretic wrinkle reduction - Google Patents

Process and system for iontophoretic wrinkle reduction Download PDF

Info

Publication number
US20180193637A1
US20180193637A1 US15/918,441 US201815918441A US2018193637A1 US 20180193637 A1 US20180193637 A1 US 20180193637A1 US 201815918441 A US201815918441 A US 201815918441A US 2018193637 A1 US2018193637 A1 US 2018193637A1
Authority
US
United States
Prior art keywords
patch
skin
assembly
chemical composition
current
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/918,441
Inventor
Raymond J. Francis
John Trengrove
Gregory Hunt
Josh Hoyt
Jim Thorne
Darrick Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Medical Pharmaceuticals Corp
Original Assignee
University Medical Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Medical Pharmaceuticals Corp filed Critical University Medical Pharmaceuticals Corp
Priority to US15/918,441 priority Critical patent/US20180193637A1/en
Publication of US20180193637A1 publication Critical patent/US20180193637A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/20Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • AHUMAN NECESSITIES
    • A45HAND OR TRAVELLING ARTICLES
    • A45DHAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
    • A45D44/00Other cosmetic or toiletry articles, e.g. for hairdressers' rooms
    • A45D44/22Face shaping devices, e.g. chin straps; Wrinkle removers, e.g. stretching the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/20Applying electric currents by contact electrodes continuous direct currents
    • A61N1/22Electromedical belts, e.g. neck chains, armbands
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/328Applying electric currents by contact electrodes alternating or intermittent currents for improving the appearance of the skin, e.g. facial toning or wrinkle treatment

Definitions

  • the present disclosure relates and is directed to a process or method of use and a system including a disposable patch to treat wrinkles and fine lines with a chemical composition administered by iontophoresis.
  • moisturizers containing amino acids play a significant role in skin care by increasing skin elasticity and smoothing the skin.
  • anti-aging active agents are known to change the skin condition by smoothing and tightening.
  • Chemical compositions may be administered topically, such as lotions, or administered through transdermal patches. Additionally, chemical compositions may be administered by direct injection. Chemical compositions presently available include those which moisturize the outer skin or epidermis. Other compositions tend to promote cell growth in the skin. Other treatments of wrinkles and fine lines include botulinum toxin (marketed under the trademark Botox®) which inhibits neurotransmission in nerve cells, thereby causing contracted muscles to relax.
  • Botox® botulinum toxin
  • Fahim U.S. Pat. No. 4,372,296 discloses topical treatment of acne with zinc salt and ascorbic acid in a pharmaceutical carrier which is applied with ultra sonic vibrations.
  • Stephen et al. (U.S. Pat. No. 4,979,938) disclose a method of treating acne using an applicator electrode having a solution capable of producing hydroxyl ions.
  • An applicator electrode is placed against the skin and a voltage differential is applied to produce and drive hydroxyl ions into the skin tissue.
  • Sun et al. U.S. Pat. No. 7,479,133 discloses a device for treating acne or rosacea by applying an electrical charge with two conductive electrodes in communication with a carrier containing an electrolyte.
  • Durand patent publications U.S. Patent Application Publication Nos. 2009/0048556 and 2009/0149800 disclose a drug delivery system including a pair of electrodes coupled to drug reservoirs 24 controlled by a microprocessor 12 .
  • the microprocessor may be programmed through a wireless signal receiver.
  • the present disclosure is directed to a process or method of use and a system for wrinkle reduction.
  • the system includes a patch assembly applied and adhesively secured to the skin of the consumer.
  • Each patch assembly includes a substantially planar top sheet and a substantially planar substrate. Connectors or snaps pass through the top sheet and substrate. On the substrate is a layer of a chemical composition including active ingredients and an adhesive in order to adhere to the skin.
  • the patch assembly or assemblies are connectable to a detachable electronic locket assembly.
  • the locket assembly may include a housing to form an enclosure. Within the enclosure of the housing is a battery which powers a microprocessor based controller or printed circuit board (PCB).
  • the controller is wired to a pair of electrodes through wires to a wiring harness.
  • the housing, the battery and the controller are suspended from the wiring harness.
  • the patch assembly or assemblies are positioned and aligned on the skin so that the chemical composition is in contact with and applied to the skin.
  • a pair of electrodes arc connected to the connectors or snaps of the patch assembly.
  • a current is applied from the locket assembly through the electrodes into the chemical composition of the patch assembly for a selected time period.
  • the active ingredients of the chemical composition are propelled into the skin of the consumer in order to relax the skin.
  • the current is stopped and the patch assembly is removed.
  • the patch assembly may then be disconnected from the locket assembly.
  • the patch assembly may thereafter be discarded and the locket assembly may be reused.
  • FIG. 1 is an illustration of a first preferred embodiment of a process and system for iontophoretic wrinkle reduction in accordance with the present disclosure
  • FIG. 2A illustrates a prospective view and FIG. 2B is an exploded view of patch assemblies of the first preferred embodiment of the present disclosure
  • FIG. 3A is a patch assembly of a second preferred embodiment while FIG. 3B is an exploded view of the patch assembly shown in FIG. 3A ;
  • FIG. 4 illustrates an exploded view of an electronic locket assembly utilized in connection with the present disclosure
  • FIGS. 5A, 5B and 5C show alternate views of the lock assembly shown in FIG. 4 ;
  • FIG. 5D is a sectional view taken through section line D-D of FIG. 5A ;
  • FIG. 6 is a diagrammatic flow chart of the process or method of application of the present disclosure.
  • FIG. 7 illustrates a schematic representation of delivery of the electric current cycle during usage of the present disclosure.
  • the present disclosure includes at least two preferred embodiments—a first preferred embodiment utilized on the skin surrounding the eyes of a consumer and a second preferred embodiment utilized on the forehead and bridge of the nose of a consumer.
  • FIG. 1 is an illustration of the first preferred embodiment 10 of the present disclosure surrounding the eyes of a consumer.
  • a pair of patch assemblies 12 and 14 are applied and adhesively secured to the skin of a consumer surrounding the eyes.
  • FIG. 2A illustrates a perspective view of the patch assemblies 12 and 14 prior to use and FIG. 2B is an exploded view of the patch assemblies 12 and 14 illustrating the components thereof.
  • Each of the patch assemblies 12 and 14 may include a substantially planar top sheet 16 and 18 , respectively.
  • the patch assemblies 12 and 14 may also include a substantially planar substrate 20 and 22 , respectively.
  • top sheet 16 and 18 and the substrates 20 and 22 each have holes or apertures which are aligned in order to receive conductive connectors or snaps 24 and 26 that pass therethrough.
  • Each of the connectors or snaps may be in two-part form. In one non-limiting example, known type electro-mechanical connectors may be utilized.
  • Adjacent and on the substrates 20 and 22 are layers of a chemical composition, which may be in the nature of a hydrogel 28 and 30 , respectively.
  • the hydrogel 28 and 30 will contain active ingredients of the chemical composition and may also include an adhesive in order to adhere to the skin.
  • the active ingredients may include hyaluronic acid, stressed yeast cell lysate, yeast cell derivative, and cross-linked synthetically derived protein.
  • the hyaluronic acid may be in the range of 0.1 to 15%.
  • the hydrogel 28 and 30 are in fluid communication with the connections or snaps 24 and 26 . Accordingly, current or voltage delivered to the connectors or snaps is delivered to the hydrogel.
  • a conductor 21 shown in FIGS. 3A-F and 4 A- 4 E, such as a conductive carbon ink, may be added to the substrate layers 20 , 22 to improve the conductivity of the electrode assembly.
  • the patch assemblies 12 and 14 may be stored and transported on a release liner sheet 32 .
  • the patch assemblies may be easily peeled off or removed from the liner sheet.
  • the entire assemblies and the liner sheet 32 may be stored in a pouch 34 .
  • FIG. 3A A second preferred embodiment of the present disclosure to be applied to the forehead and bridge of the nose is shown in assembled form in FIG. 3A and is shown exploded in FIG. 3B .
  • the second preferred embodiment includes a patch assembly 42 shown fully assembled in FIG. 3A prior to use.
  • the patch assembly 42 may include a substantially planar top sheet 44 and an aligned substantially planar substrate 46 .
  • the top sheet 44 and substrate 46 each include aligned holes or apertures to receive a pair of connectors or snaps 48 and 50 .
  • the patch assembly includes a layer of chemical composition in the hydrogel 52 .
  • the entire patch assembly 42 may be transported and stored on a liner sheet 54 .
  • the patch assembly 42 and the liner sheet may be stored in a pouch 56 .
  • the patch assemblies are disposable after use.
  • the patch assemblies are connectable to an electronic locket assembly 60 .
  • FIG. 4 illustrates an exploded view of the electronic locket assembly 60 .
  • FIGS. 5A, 5B and 5C show alternate views of the locket assembly 60 with FIG. 5D illustrating a sectional view taken through section line D-D of FIG. 5A .
  • the locket assembly 60 may include a front housing 62 which mates with a rear housing 64 to form an enclosure. Attached to the housing may be an optional clasp or clip 66 .
  • a battery 68 Within the enclosure of the housing is a battery 68 which powers a microprocessor based controller or printed circuit board (PCB) 70 .
  • a contact or contacts 72 connect the battery 68 to the controller 70 .
  • PCB printed circuit board
  • the microprocessor based controller 70 is, in turn, wired to a pair of electrodes 74 and 76 through wires or a wiring harness 78 .
  • the housing 62 and 64 , the battery 68 and controller 70 may hang from or be suspended from the wiring harness 78 .
  • the process and system of the present disclosure uses iontophoresis as the motive force for transdermal delivery of a defined amount of active ingredients.
  • the patch assembly or assemblies are removed from the storage pouch and removed from the liner sheet and then positioned and aligned on the skin so that the chemical composition is in contact with and applied to the skin.
  • the adhesive in the chemical composition serves to removably secure the patch assembly to the skin.
  • the pair of electrodes 74 and 76 are connected to the connectors or snaps of the patch assembly either in advance of application to the skin or after application. The process is continued by electronically activating the patch assembly.
  • a current is applied from the locket assembly 60 through the electrodes 74 and 76 into the chemical composition of the patch assembly for a selected time period.
  • the active ingredients of the chemical composition are propelled into the skin of the consumer in order to relax the skin or achieve other beneficial results.
  • the current optionally may be reversed once or at least twice, for example, as illustrated in FIG. 7 .
  • the current is stopped and the patch assembly is removed from the skin.
  • the patch assembly may be disconnected from the locket assembly 60 .
  • the patch assembly may thereafter be discarded.
  • any residue of the chemical composition may be massaged into the skin.
  • the procedure may be periodically repeated.
  • FIG. 6 illustrates a diagrammatic, flow chart of the process or method of application of the current during the delivery cycle of the disclosure.
  • the microprocessor based controller 70 will conduct a self initialization test as shown in Box 84 .
  • the process can be started conventionally by a button or switch or may be activated by a change in resistance between the electrodes triggered by skin contact.
  • a solid red LED or other indicator will be provided as shown at Box 86 and the device will not be used. If the initialization test is satisfactory, as shown in Diamond 88 , proper functioning will be indicated by a green LED as shown at Box 90 .
  • FIG. 7 illustrates a schematic representation of the current cycle.
  • the current will be ramped up and then held for a predetermined time period.
  • the power supply and/or the controller can be configured to apply no current through the electrodes 74 and 76 . Thereafter, the current will be ramped down and the polarity changed.
  • a mid-cycle self diagnostic test may be performed by the controller as shown at box 98 . If an error is detected, a red LED will be displayed as shown at Box 100 and the procedure will be terminated. If the diagnostic test is satisfactory, as shown at Diamond 102 , the procedure will be continued until the time period is completed as shown at Diamond 104 . When the time period has been completed, the green light ceases to blink and remains on for a period of time to indicate the end of the procedure as shown at Box 106 .
  • the patch assembly is removed from the skin and the locket assembly 60 is detached from the patch assembly.
  • the locket assembly may be reused.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Electrotherapy Devices (AREA)
  • Massaging Devices (AREA)

Abstract

A method and related systems and apparatuses for wrinkle reduction. The method includes the steps of positioning and applying a patch to skin of a consumer and adhesively securing the patch to the skin. A chemical composition on the patch includes both active ingredients and adhesive. A pair of electrodes are connected to a battery-driven, microprocessor-based controller. A current is applied through the electrodes in the patch for a selected time. The chemical composition in the patch is propelled into the consumer through use of the current in order to relax the skin or the consumer. The patch is removed and any residue of the chemical composition is massaged into the skin.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 CFR 1.57.
  • This application is a continuation of copending U.S. patent application Ser. No. 14/298,190, filed on Jun. 6, 2014, which is a continuation of U.S. patent application Ser. No. 12/970,224, filed Dec. 16, 2010, now U.S. Pat. No. 8,747,383, which claims priority to U.S. Provisional Patent Application Ser. No. 61/288,088, filed Dec. 18, 2009, each are incorporated in their entireties herein by reference and for all purposes.
  • BACKGROUND Field
  • The present disclosure relates and is directed to a process or method of use and a system including a disposable patch to treat wrinkles and fine lines with a chemical composition administered by iontophoresis.
  • Prior Art
  • There are various known procedures and various known chemical compositions for treating, reducing or preventing fine lines or wrinkles of the facial skin. It is known that moisturizers containing amino acids play a significant role in skin care by increasing skin elasticity and smoothing the skin. In addition, anti-aging active agents are known to change the skin condition by smoothing and tightening.
  • Chemical compositions may be administered topically, such as lotions, or administered through transdermal patches. Additionally, chemical compositions may be administered by direct injection. Chemical compositions presently available include those which moisturize the outer skin or epidermis. Other compositions tend to promote cell growth in the skin. Other treatments of wrinkles and fine lines include botulinum toxin (marketed under the trademark Botox®) which inhibits neurotransmission in nerve cells, thereby causing contracted muscles to relax.
  • In order to increase the speed and effectiveness of delivery of chemical compositions for treatment, it is known to utilize sonic vibrations. For example, Fahim (U.S. Pat. No. 4,372,296) discloses topical treatment of acne with zinc salt and ascorbic acid in a pharmaceutical carrier which is applied with ultra sonic vibrations.
  • Stephen et al. (U.S. Pat. No. 4,979,938) disclose a method of treating acne using an applicator electrode having a solution capable of producing hydroxyl ions. An applicator electrode is placed against the skin and a voltage differential is applied to produce and drive hydroxyl ions into the skin tissue.
  • Sun et al. (U.S. Pat. No. 7,479,133) discloses a device for treating acne or rosacea by applying an electrical charge with two conductive electrodes in communication with a carrier containing an electrolyte.
  • More recently, the Durand patent publications (U.S. Patent Application Publication Nos. 2009/0048556 and 2009/0149800) disclose a drug delivery system including a pair of electrodes coupled to drug reservoirs 24 controlled by a microprocessor 12. The microprocessor may be programmed through a wireless signal receiver.
  • Notwithstanding the forgoing, there remains a need for an effective, simple, non-invasive and non-surgical process and system utilizing a disposable patch for treating wrinkles and fine lines.
  • There also remains a need for a process and system utilizing a disposable patch for wrinkle reduction which may be manufactured at low-cost and high volume.
  • There also remains a need for a process and system utilizing a disposable patch for wrinkle reduction with precision timing of delivery of active ingredients.
  • There also remains a need for an apparatus having an adhesive disposable patch with a plurality of active ingredients, a power supply, and a controller in communication with the power supply controlling current using a ramping current profile.
  • SUMMARY
  • The present disclosure is directed to a process or method of use and a system for wrinkle reduction.
  • The system includes a patch assembly applied and adhesively secured to the skin of the consumer. Each patch assembly includes a substantially planar top sheet and a substantially planar substrate. Connectors or snaps pass through the top sheet and substrate. On the substrate is a layer of a chemical composition including active ingredients and an adhesive in order to adhere to the skin.
  • The patch assembly or assemblies are connectable to a detachable electronic locket assembly. The locket assembly may include a housing to form an enclosure. Within the enclosure of the housing is a battery which powers a microprocessor based controller or printed circuit board (PCB). The controller is wired to a pair of electrodes through wires to a wiring harness. The housing, the battery and the controller are suspended from the wiring harness.
  • In order to use the disclosed embodiments, the patch assembly or assemblies are positioned and aligned on the skin so that the chemical composition is in contact with and applied to the skin. A pair of electrodes arc connected to the connectors or snaps of the patch assembly.
  • A current is applied from the locket assembly through the electrodes into the chemical composition of the patch assembly for a selected time period. The active ingredients of the chemical composition are propelled into the skin of the consumer in order to relax the skin. After a selected period of time, the current is stopped and the patch assembly is removed.
  • The patch assembly may then be disconnected from the locket assembly. The patch assembly may thereafter be discarded and the locket assembly may be reused.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is an illustration of a first preferred embodiment of a process and system for iontophoretic wrinkle reduction in accordance with the present disclosure;
  • FIG. 2A illustrates a prospective view and FIG. 2B is an exploded view of patch assemblies of the first preferred embodiment of the present disclosure;
  • FIG. 3A is a patch assembly of a second preferred embodiment while FIG. 3B is an exploded view of the patch assembly shown in FIG. 3A;
  • FIG. 4 illustrates an exploded view of an electronic locket assembly utilized in connection with the present disclosure;
  • FIGS. 5A, 5B and 5C show alternate views of the lock assembly shown in FIG. 4;
  • FIG. 5D is a sectional view taken through section line D-D of FIG. 5A;
  • FIG. 6 is a diagrammatic flow chart of the process or method of application of the present disclosure; and
  • FIG. 7 illustrates a schematic representation of delivery of the electric current cycle during usage of the present disclosure.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The embodiments discussed herein are merely illustrative of specific manners in which to make and use the disclosed embodiments and are not to be interpreted as limiting the scope of the present disclosure.
  • While the disclosure has been described with a certain degree of particularity, it is to be noted that many modifications may be made in the details of the construction and the arrangement of selected components without departing from the spirit and scope of this disclosure. It is understood that the disclosure is not limited to the embodiments set forth herein for purposes or exemplification.
  • The present disclosure includes at least two preferred embodiments—a first preferred embodiment utilized on the skin surrounding the eyes of a consumer and a second preferred embodiment utilized on the forehead and bridge of the nose of a consumer.
  • Referring to the drawings in detail, FIG. 1 is an illustration of the first preferred embodiment 10 of the present disclosure surrounding the eyes of a consumer. As will be described herein in detail, a pair of patch assemblies 12 and 14 are applied and adhesively secured to the skin of a consumer surrounding the eyes.
  • FIG. 2A illustrates a perspective view of the patch assemblies 12 and 14 prior to use and FIG. 2B is an exploded view of the patch assemblies 12 and 14 illustrating the components thereof.
  • Each of the patch assemblies 12 and 14 may include a substantially planar top sheet 16 and 18, respectively. The patch assemblies 12 and 14 may also include a substantially planar substrate 20 and 22, respectively.
  • The top sheet 16 and 18 and the substrates 20 and 22 each have holes or apertures which are aligned in order to receive conductive connectors or snaps 24 and 26 that pass therethrough. Each of the connectors or snaps may be in two-part form. In one non-limiting example, known type electro-mechanical connectors may be utilized.
  • Adjacent and on the substrates 20 and 22 are layers of a chemical composition, which may be in the nature of a hydrogel 28 and 30, respectively. The hydrogel 28 and 30 will contain active ingredients of the chemical composition and may also include an adhesive in order to adhere to the skin. The active ingredients may include hyaluronic acid, stressed yeast cell lysate, yeast cell derivative, and cross-linked synthetically derived protein. The hyaluronic acid may be in the range of 0.1 to 15%.
  • The hydrogel 28 and 30 are in fluid communication with the connections or snaps 24 and 26. Accordingly, current or voltage delivered to the connectors or snaps is delivered to the hydrogel. Alternatively or additionally, a conductor 21 (shown in FIGS. 3A-F and 4A-4E), such as a conductive carbon ink, may be added to the substrate layers 20, 22 to improve the conductivity of the electrode assembly.
  • The patch assemblies 12 and 14 may be stored and transported on a release liner sheet 32. The patch assemblies may be easily peeled off or removed from the liner sheet. The entire assemblies and the liner sheet 32 may be stored in a pouch 34.
  • A second preferred embodiment of the present disclosure to be applied to the forehead and bridge of the nose is shown in assembled form in FIG. 3A and is shown exploded in FIG. 3B.
  • The second preferred embodiment includes a patch assembly 42 shown fully assembled in FIG. 3A prior to use. The patch assembly 42 may include a substantially planar top sheet 44 and an aligned substantially planar substrate 46. The top sheet 44 and substrate 46 each include aligned holes or apertures to receive a pair of connectors or snaps 48 and 50.
  • The patch assembly includes a layer of chemical composition in the hydrogel 52. The entire patch assembly 42 may be transported and stored on a liner sheet 54. The patch assembly 42 and the liner sheet may be stored in a pouch 56.
  • In a preferred arrangement, the patch assemblies are disposable after use. In each embodiment, the patch assemblies are connectable to an electronic locket assembly 60.
  • FIG. 4 illustrates an exploded view of the electronic locket assembly 60. FIGS. 5A, 5B and 5C show alternate views of the locket assembly 60 with FIG. 5D illustrating a sectional view taken through section line D-D of FIG. 5A. The locket assembly 60 may include a front housing 62 which mates with a rear housing 64 to form an enclosure. Attached to the housing may be an optional clasp or clip 66. Within the enclosure of the housing is a battery 68 which powers a microprocessor based controller or printed circuit board (PCB) 70. A contact or contacts 72 connect the battery 68 to the controller 70.
  • The microprocessor based controller 70 is, in turn, wired to a pair of electrodes 74 and 76 through wires or a wiring harness 78.
  • The housing 62 and 64, the battery 68 and controller 70 may hang from or be suspended from the wiring harness 78.
  • The process and system of the present disclosure uses iontophoresis as the motive force for transdermal delivery of a defined amount of active ingredients.
  • In order to use the system of the present disclosure, initially, the patch assembly or assemblies are removed from the storage pouch and removed from the liner sheet and then positioned and aligned on the skin so that the chemical composition is in contact with and applied to the skin. The adhesive in the chemical composition serves to removably secure the patch assembly to the skin.
  • The pair of electrodes 74 and 76 are connected to the connectors or snaps of the patch assembly either in advance of application to the skin or after application. The process is continued by electronically activating the patch assembly.
  • Thereafter, a current is applied from the locket assembly 60 through the electrodes 74 and 76 into the chemical composition of the patch assembly for a selected time period. The active ingredients of the chemical composition are propelled into the skin of the consumer in order to relax the skin or achieve other beneficial results. After a selected period of time, the current optionally may be reversed once or at least twice, for example, as illustrated in FIG. 7. Eventually, the current is stopped and the patch assembly is removed from the skin. The patch assembly may be disconnected from the locket assembly 60. The patch assembly may thereafter be discarded.
  • As an additional step or measure, after the patch assembly is removed, any residue of the chemical composition may be massaged into the skin. The procedure may be periodically repeated.
  • FIG. 6 illustrates a diagrammatic, flow chart of the process or method of application of the current during the delivery cycle of the disclosure. After start of the procedure, as shown in Box 82, the microprocessor based controller 70 will conduct a self initialization test as shown in Box 84. The process can be started conventionally by a button or switch or may be activated by a change in resistance between the electrodes triggered by skin contact.
  • If the initialization test does not result in an affirmative outcome, a solid red LED or other indicator will be provided as shown at Box 86 and the device will not be used. If the initialization test is satisfactory, as shown in Diamond 88, proper functioning will be indicated by a green LED as shown at Box 90.
  • Current to the device will be permitted to ramp up and a timer will be started as shown at Box 92. While the current is being delivered through the chemical composition and into the skin, a blinking green LED will be employed, as shown at Box 94.
  • The polarity of the current will be cycled or alternated as shown at Box 96. FIG. 7 illustrates a schematic representation of the current cycle. The current will be ramped up and then held for a predetermined time period. During the predetermined time period, the power supply and/or the controller can be configured to apply no current through the electrodes 74 and 76. Thereafter, the current will be ramped down and the polarity changed.
  • Additionally, a mid-cycle self diagnostic test may be performed by the controller as shown at box 98. If an error is detected, a red LED will be displayed as shown at Box 100 and the procedure will be terminated. If the diagnostic test is satisfactory, as shown at Diamond 102, the procedure will be continued until the time period is completed as shown at Diamond 104. When the time period has been completed, the green light ceases to blink and remains on for a period of time to indicate the end of the procedure as shown at Box 106.
  • Thereafter, the patch assembly is removed from the skin and the locket assembly 60 is detached from the patch assembly. The locket assembly may be reused.
  • If, at any time after the cycle has started, one of the electrodes or patch assemblies falls off, an error condition is signaled. If not reconnected within a reasonable time, the system defaults to an off position.
  • Whereas, the present disclosure has been described in relation to the drawings attached hereto, it should be understood that other and further modifications, apart from those shown or suggested herein, may be made within the spirit and scope of this disclosure.

Claims (1)

What is claimed is:
1. A wrinkle-reducing apparatus, comprising:
a patch comprising a hydrogel layer coupled with an adhesive layer; and
a power supply in communication with the hydrogel layer via an electrode,
wherein the power supply is configured to apply an iontophoretic current to the hydrogel layer through the electrode.
US15/918,441 2009-12-18 2018-03-12 Process and system for iontophoretic wrinkle reduction Abandoned US20180193637A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/918,441 US20180193637A1 (en) 2009-12-18 2018-03-12 Process and system for iontophoretic wrinkle reduction

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28808809P 2009-12-18 2009-12-18
US12/970,224 US8747383B2 (en) 2009-12-18 2010-12-16 Process and system for iontophoretic wrinkle reduction
US14/298,190 US9913977B2 (en) 2009-12-18 2014-06-06 Process and system for iontophoretic wrinkle reduction
US15/918,441 US20180193637A1 (en) 2009-12-18 2018-03-12 Process and system for iontophoretic wrinkle reduction

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/298,190 Continuation US9913977B2 (en) 2009-12-18 2014-06-06 Process and system for iontophoretic wrinkle reduction

Publications (1)

Publication Number Publication Date
US20180193637A1 true US20180193637A1 (en) 2018-07-12

Family

ID=44167938

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/970,224 Active 2032-03-26 US8747383B2 (en) 2009-12-18 2010-12-16 Process and system for iontophoretic wrinkle reduction
US14/298,190 Active US9913977B2 (en) 2009-12-18 2014-06-06 Process and system for iontophoretic wrinkle reduction
US15/918,441 Abandoned US20180193637A1 (en) 2009-12-18 2018-03-12 Process and system for iontophoretic wrinkle reduction

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US12/970,224 Active 2032-03-26 US8747383B2 (en) 2009-12-18 2010-12-16 Process and system for iontophoretic wrinkle reduction
US14/298,190 Active US9913977B2 (en) 2009-12-18 2014-06-06 Process and system for iontophoretic wrinkle reduction

Country Status (4)

Country Link
US (3) US8747383B2 (en)
EP (1) EP2512283A4 (en)
RU (1) RU2012130389A (en)
WO (1) WO2011075646A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100286590A1 (en) * 2009-05-08 2010-11-11 Isis Biopolymer Llc Iontophoretic device with improved counterelectrode
US20110092881A1 (en) * 2009-05-08 2011-04-21 Isis Biopolymer Inc. Iontophoretic device with contact sensor
US8747383B2 (en) 2009-12-18 2014-06-10 University Medical Pharmaceuticals Corp. Process and system for iontophoretic wrinkle reduction
US20130012891A1 (en) * 2011-07-05 2013-01-10 Yossi Gross Skin-treatment and drug-delivery devices
CN109688864A (en) * 2016-05-02 2019-04-26 普尔普勒技术公司 System and method for showing digital picture on Digital Image Display box
EP3520649B1 (en) * 2016-09-27 2021-01-20 Panasonic Intellectual Property Management Co., Ltd. Thin film affixing device
US11642504B2 (en) * 2017-08-07 2023-05-09 Nippon Telegraph And Telephone Corporation Sheet mask comprising a battery part
US10092478B1 (en) * 2017-09-06 2018-10-09 Noah Amit Method and system for treating skin associated with the face and neck
WO2024080248A1 (en) * 2022-10-13 2024-04-18 ヤーマン株式会社 Beauty mask
CN118718238B (en) * 2024-09-02 2024-11-22 北京意安平顺网络科技有限公司 Iontophoresis patch for facial skin and method of manufacture

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050000455A1 (en) * 2003-07-01 2005-01-06 Havermans Cornelis Christianus Franciscus Milking installation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372296A (en) 1980-11-26 1983-02-08 Fahim Mostafa S Treatment of acne and skin disorders and compositions therefor
US4406658A (en) * 1981-03-06 1983-09-27 Medtronic, Inc. Iontophoretic device with reversible polarity
US4702732A (en) * 1984-12-24 1987-10-27 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands
JPS6499A (en) 1987-03-17 1989-01-05 Nippon Kayaku Co Ltd 23-phenylsteroids and production thereof
US4979938A (en) 1989-05-11 1990-12-25 Iomed, Inc. Method of iontophoretically treating acne, furuncles and like skin disorders
US5505949A (en) * 1994-10-13 1996-04-09 Benitez; Juan E. Topical treatment for acne
JPH11505158A (en) 1995-05-15 1999-05-18 アルザ・コーポレーション Electric transport device with reusable controller
JP2768456B2 (en) 1995-12-22 1998-06-25 株式会社ジャパンギャルズ Makeup mask
US6175763B1 (en) * 1996-03-29 2001-01-16 Alza Corporation Electrotransport drug delivery device having tactile signaling means
FR2755372B1 (en) * 1996-11-07 1998-12-24 Elf Aquitaine IONOPHORESIS DEVICE COMPRISING AT LEAST ONE MEMBRANE ELECTRODE ASSEMBLY FOR THE TRANSCUTANEOUS ADMINISTRATION OF ACTIVE PRINCIPLES TO A SUBJECT
US5882677A (en) * 1997-09-30 1999-03-16 Becton Dickinson And Company Iontophoretic patch with hydrogel reservoir
EP1674044B1 (en) * 1997-10-09 2015-08-19 Aesculap AG Systems for organ resection
US6792306B2 (en) * 2000-03-10 2004-09-14 Biophoretic Therapeutic Systems, Llc Finger-mounted electrokinetic delivery system for self-administration of medicaments and methods therefor
US6590441B2 (en) 2001-06-01 2003-07-08 Qualcomm Incorporated System and method for tuning a VLSI circuit
US7643874B2 (en) * 2001-10-24 2010-01-05 Power Paper Ltd. Dermal patch
KR101028788B1 (en) 2001-10-24 2011-04-14 파워 페이퍼 리미티드 Controlled Delivery Device and Method of Active Material into Skin
US6823202B2 (en) * 2002-04-01 2004-11-23 Iomed, Inc. Iontophoretic power supply
US6866856B2 (en) 2002-12-31 2005-03-15 Avon Products, Inc. Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
KR200327534Y1 (en) 2003-05-30 2003-09-22 홍명학 Apparatus for caring skin
US7479133B2 (en) 2003-06-30 2009-01-20 Johnson & Johnson Consumer Companies, Inc. Methods of treating acne and rosacea with galvanic generated electricity
US7477941B2 (en) * 2003-06-30 2009-01-13 Johnson & Johnson Consumer Companies, Inc. Methods of exfoliating the skin with electricity
JP2005245521A (en) 2004-03-01 2005-09-15 Japan Natural Laboratory Co Ltd Beautiful skin or beauty system using iontophoresis device, ultrasonic facial device and cosmetic additives.
US20060100567A1 (en) * 2004-07-30 2006-05-11 Rocky Mountain Biosystems, Inc Microsurgical tissue treatment system
EP1671670A1 (en) 2004-12-14 2006-06-21 STX Sprl Apparatus for electrically inhibiting facial muscles
KR200403033Y1 (en) 2005-09-16 2005-12-07 이상홍 Portable skin care device for beauty pack
US20070092571A1 (en) * 2005-10-25 2007-04-26 Schur Henry B Non-irritating formulation and method for the intradermal delivery of substances
US7945320B2 (en) 2007-08-17 2011-05-17 Isis Biopolymer, Inc. Iontophoretic drug delivery system
EP2242537A1 (en) 2007-12-10 2010-10-27 Isis Biopolymer LLC Iontophoretic drug delivery device and software application
US20090299267A1 (en) 2008-05-28 2009-12-03 Isis Biopolymer Llc Iontophoretic drug delivery system with procedure window
US20100286590A1 (en) 2009-05-08 2010-11-11 Isis Biopolymer Llc Iontophoretic device with improved counterelectrode
US8747383B2 (en) 2009-12-18 2014-06-10 University Medical Pharmaceuticals Corp. Process and system for iontophoretic wrinkle reduction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050000455A1 (en) * 2003-07-01 2005-01-06 Havermans Cornelis Christianus Franciscus Milking installation

Also Published As

Publication number Publication date
RU2012130389A (en) 2014-01-27
US20110190724A1 (en) 2011-08-04
EP2512283A2 (en) 2012-10-24
EP2512283A4 (en) 2013-07-31
WO2011075646A3 (en) 2011-10-27
US8747383B2 (en) 2014-06-10
US20140288527A1 (en) 2014-09-25
WO2011075646A2 (en) 2011-06-23
US9913977B2 (en) 2018-03-13

Similar Documents

Publication Publication Date Title
US20180193637A1 (en) Process and system for iontophoretic wrinkle reduction
US11896821B2 (en) Systems and methods for tissue treatment
US7979117B2 (en) Device and method for controlled delivery of active substance into the skin
US7643874B2 (en) Dermal patch
CN1607970B (en) Skin patch
US20140378555A1 (en) Facial treatment device
AU2002363106A1 (en) Device and method for controlled delivery of active substance into the skin
US20100228180A1 (en) Power Source Electrode Treatment Device
AU2002347567A1 (en) Dermal patch
KR20110002210A (en) Functional stagnation
KR20140146914A (en) Connector device being connected to earphone connecting port of mobile terminal for providing electrical stimulus through electrical pad attached to skin surface
KR100899100B1 (en) Skin treatment apparatus
KR20100080647A (en) Electric low frequency type roller niddle
TWI274583B (en) Device for stimulating muscle to contract and relax
KR20230091270A (en) A collagen-producing portable beauty device that maximizes the anti-aging effect that stimulates skin cells using microcurrents
CN113797443A (en) A remote intelligent health biological device

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION